|
|
 |
Artículos seleccionados
Drugs of the Future
Vol. 32, No. 11, November 2007
Keratinocyte growth factor receptor tyrosine kinase antagonists for the prevention of metastatic cancer progression
Vol. 32, No. 10, October 2007
Inhibitors of the MDM2-p53 interaction as anticancer drugs
Vol. 32, No. 1, January 2007
Bevirimat. Anti-HIV Agent, Viral Maturation Inhibitor
Fluticasone Furoate. Glucocorticoid Receptor Agonist, Intranasal Corticosteroid Vol. 31, No. 8, August 2006
GABAA receptors as targets for different classes of drugs
Therapy of somatoform disorders Vol. 31, No. 2, February 2006
The MC4 receptor as a drug discovery target Vol. 30, No. 8, August 2005
The role of cannabinoids in preventing the neurodegenerative process occurring in Alzheimer's disease Vol. 30, No. 5, May 2005
Drug discovery targets: 5-HT6 receptor Vol. 30, No. 3, March 2005
DNA minor groove binding agents Vol. 30, No. 2, February 2005
Organic carbamates in drug development. Part II: antimicrobial agents - recent reports Suprabhat Ray, Seema R. Pathak, Devdutt Chaturvedi Vol. 29, No. 8, August 2004
Role of the glucagon receptor in glucose homeostasis: a therapeutic target to improve glycemic control in type 2 diabetes. K.W. Sloop, M.D. Michael Vol. 29, No. 4, April 2004
Thalidomide as a multitarget drug and its application as a template for drug design Yuichi Hashimoto, Aya Tanatani, Kazuo Nagasawa and Hiroyuki Miyachi Vol. 29, No. 1, January 2004
iNOS homodimerization as a target for potential new therapeutic agents F. Konno, M. Ohtsuka Vol. 28, No. 5, May 2003
Hepatitis C virus NS3 serine protease as a drug discovery
target F. McPhee, K.-S. Yeung, A.C. Good, N.A. Meanwell Vol. 28, No. 1, January 2003
RNA interference: an exciting new approach for target
validation, gene expression analysis and therapeutics R.P. Iyer, S.N.
Kuchimanchi, R.K. Pandey
Drug News & Perspectives
Vol. 20, No. 7, September 2007
The Role of Cholinergic Balance Perturbation in Neurological Diseases It appears that the cholinergic balance is not restricted to neurons and synapses, but may also involve immune reactions.
Vol. 20, No. 6, July/August 2007
Multidrug Resistance in Cancer: Its Mechanism and its Modulation Together with the knowledge obtained on the molecular difference between cancer and normal cells, the understanding of membrane transport processes will facilitate the development of therapeutic strategies to prevent or circumvent resistance to treatment.
Vol. 20, No. 1, January/February 2007
The Year's New Drugs and Biologics-2006 This year, 41 new products, including new chemical entities and biologics for therapeutic use as well as new diagnostic agents, reached their first markets in 2006.
Overcoming the Challenges in the Pharma/Biotech Industry As patents expire and innovation declines, the pharma/biotech industry must pursue aggressive strategies and adopt a fresh perspective to stay ahead. Vol. 19, No. 6, July/August 2006
CDK/GSK-3 Inhibitors as a New Approach for the Treatment of Proliferative Renal Diseases With considerable attention being received from the pharmaceutical industry, CDK/GSK-3 inhibitors may emerge as effective therapeutic agents for proliferative renal diseases. Vol. 19, No. 1, January/February 2006
The Search for Novel Avenues for the Therapy and Prevention of Alzheimer's Disease The Search for Novel Avenues for the Therapy and Prevention of Alzheimer's Disease. Vol. 18, No. 7, September 2005
Leptin and Cardiovascular Diseases Leptin has been shown to increase sympathetic nerve activity, stimulate generation of reactive oxygen species, upregulate endothelin-1 production and potentiate platelet aggregation. Vol. 18, No. 5, June 2005
JAK Protein Kinase Inhibitors The success of CP-690550 in animal organ transplant models makes prevention of allograft rejection the most likely application of JAK inhibitors. Vol. 18, No. 3, April 2005
TRPV1 Receptor: A Target for the Treatment of Pain, Cough, Airway Disease and Urinary Incontinence There is evidence that TRPV1 plays a role in the development of pathophysiological changes and symptoms in several diseases. Vol. 18, No. 1, January/February 2005
Oxidative Damage and Alzheimer's Disease: Are Antioxidant Therapies Useful?
by Paula I. Moreira, Mark A. Smith, Xiongwei Zhu, Kazuhiro Honda, Hyoung-gon Lee, Gjumrakch Aliev and George Perry
Since oxidative damage is a key phenomenon in Alzheimer's disease, treatment with antioxidants seems to be a promising approach for slowing disease progression. Vol. 17, No. 7, September 2004
Vascular NAD(P)H Oxidase as a Novel Therapeutic Target in Vascular Disease.
by Julia Brosnan
Inhibitors of vascular NAD(P)H oxidase, which has been identified as the major source of superoxide, may provide a novel therapy in cardiovascular disease. Vol. 17, No. 4, May 2004
Antiinflammatory Properties of PPARγ Agonists Following Ischemia
by Sophia Sundararajan and Gary E. Landreth
Type 2 diabetics are at high risk for vascular disease and could benefit from antiinflammatory actions of PPARγ agonists on atherosclerosis, myocardial ischemia and cerebral ischemia. Vol. 16, No. 10, December 2003
Drugs to Interfere with Orexins (Hypocretins)
by Oliver Selbach, Krister S. Eriksson and Helmut L. Haas
Development of drugs targeting the orexin system will open novel therapeutic avenues for the treatment of many neuropsychiatric and neuroendocrine disorders of eating, pain, mood, sleep and memory. Vol. 16, No. 5, June 2003
Adenosine Receptors a Targets for Drug Development
by Bertil B. Fredholm
The results obtained with pharmacological tools and genetically modified
mice have indicated a number of potential therapeutic areas for drugs
acting at adenosine receptors. Vol. 15, No. 10, May 2002
Galanin: Involvement in Behavior and Neuropathology,
and Therapeutic Potential
by Peter J. McLaughlin and John K. Robinson
We are entering an exciting period in the development of galanin
pharmacology that may lead to new drugs for the treatment of cognitive
decline and other neuro- and psychopathologies.
[Inicio]
|
|
|
|
